ASRM: Annual Meeting Handouts

Human papilloma virus (HPV) has been shown to be a causative agent in the development of anogenital warts, intraepithelial neoplasia, and invasive cancers. A quadrivalent HPV vaccine has been approved recently for use in young women ages 11 to 26 years with the intent of protecting against the most common subtypes of HPV implicated in anogenital disease (types 6, 11, 16, 18).

This symposium was held on Monday, October 15, 2007 at the American Society for Reproductive Medicine 2007 Annual Meeting in Washington, DC to explore the recent information regarding the efficacy of the vaccine, as well as discuss controversies regarding who else should be vaccinated, whether vaccination should be mandated, and if there is a role for the vaccine in protecting against HPV related disease in other sites of the body.

At the conclusion of this symposium, participants should be able to:

Summarize the current recommendations for clinical use of the quadrivalent human papillomavirus vaccine
Discuss recent epidemiological data concerning the varying degree of risk of cervical neoplasia according to type-specific HPV infection
Describe the influence of age and gender on HPV vaccination

	HPV: Clinical Significance Samantha M. Pfeifer, MD Associate Professor of Obstetrics and Gynecology University of Pennsylvania School of Medicine Philadelphia, PA

	HPV Vaccination: Influence of Age and Gender Mark Spitzer, MD Chairman, Obstetrics and Gynecology Brookdale University Hospital and Medical Center Professor of Clinical Obstetrics and Gynecology Weill Medical College of Cornell University New York City, NY

	Lessons Learned From Implementation of Hepatitis B Immunization in the United States John W. Ward, MD Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA

CME Posttest and Evaluation 1.5 CME credits available Click here All speakers were required to complete a disclosure of commercial and financial relationships with manufacturers of pharmaceuticals, laboratory supplies or medical devices and with commercial providers of medically related services. These disclosures were reviewed and potential conflicts of interest resolved by the Subcommittee on Standards of Commercial Support of the Continuing Medical Education Committee of the American Society for Reproductive Medicine. The disclosures are listed in the presentations. Supported by an educational grant from Merck.

The typical American woman spends approximately one third of her lifetime in the postmenopausal state. As the population ages, physicians are called upon increasingly to help women adjust to their postmenopausal physiology. Participants in prior educational activities have requested discussions of the physiology and pharmacotherapeutics of postmenopausal hormone therapy.

This webcast should be useful for all healthcare providers who are concerned about postmenopausal hormone therapy and how to discuss treatment options with their patients. Healthcare providers should become aware of the risks and benefits of the various preparations available. This activity is intended to meet the critical need of identifying symptoms that require treatment and discussing appropriate treatment options to provide optimal patient care.

At the conclusion of this symposium, participants should be able to:

Discuss the appropriate use of peri- and postmenopausal HT in symptomatic women.
Counsel possible users of menopausal HT about associated risks and benefits.
Develop appropriate treatment regimens for asymptomatic women who decide to use HT

	Aging, Androgens, and Female Sexual Desire: Restoring What Time Takes Away Sandra Ann Carson, MD Professor of Obstetrics and Gynecology Warren Alpert Medical School Brown University Providence, Rhode Island

	Role of Progestogens and Testosterone in Postmenopausal Women David F. Archer, MD Professor of Obstetrics and Gynecology Director CONRAD Clinical Research Center Eastern Virginia Medical School Norfolk, Virginia

	Additives to Estrogen in Challenging Cases John E. Buster, MD Professor of Obstetrics and Gynecology Warren Alpert Medical School of Brown University Providence, Rhode Island

CME Posttest and Evaluation 1.5 CME credits available Click here All speakers were required to complete a disclosure of commercial and financial relationships with manufacturers of pharmaceuticals, laboratory supplies or medical devices and with commercial providers of medically related services. These disclosures were reviewed and potential conflicts of interest resolved by the Subcommittee on Standards of Commercial Support of the Continuing Medical Education Committee of the American Society for Reproductive Medicine. The disclosures are listed in the presentations. Supported by an educational grant from Solvay Pharmaceuticals.

Return to the ASRM Annual Meeting Page

By accessing and using the ASRM Web Site, you agree to be bound by
the ASRM Web Site Terms and Conditions of Use.

View the ASRM Non Discrimination Policy

Listed on Infertility Resources
Developed and hosted by Internet Health Resources